Subtype Specific MEK – PI3 Kinase Feedback as a Therapeutic Target in Pancreatic Adenocarcinoma

Mutations in the KRAS oncogene are dominant features in pancreatic adenocarcinoma (PDA). Since KRAS itself is considered “undruggable”, targeting pathways downstream of KRAS is being explored as a rational therapeutic strategy. We investigated the consequences of MEK inhibition in a large PDA cell l...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Mirzoeva, Olga K., Collisson, Eric A., Schaefer, Peter M., Hann, Byron, Hom, Yun K., Ko, Andrew H., Korn, W. Michael
Médium: Artigo
Jazyk:Inglês
Vydáno: 2013
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC3800201/
https://ncbi.nlm.nih.gov/pubmed/23918833
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1535-7163.MCT-13-0104
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky